A differentiated approach to the prescription of angiogenesis inhibitors for diabetic macular edema

Surveillance of the eye (n=77) in 68 diabetic patients diagnosed with nonproliferative diabetic retinopathy, and diabetic macular edema (DME) without (group I) and with presence (group II) of vitreomacular traction (VMT) characters has been conducted. Methods of research are visometry, bio-micro-ophthalmoscopy, fluorescent angiography, optical coherence tomography. All patients have been intravitreally injected angiogenesis inhibitor (bevacizumab - 2,5 mg). Postoperatively, improvement of visual functions has been registered and the decrease in total (G) of the retina in the macular region in 71,2% of patients in group I and in 55,6% of patients in Group II has been mentioned. There had been observed deterioration of visual functions and traction component gain in 33,3% patients in Group II on 10-15th day observation. Deterioration has been registered in patients in group I too, but only in 23,7% of observations.